Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare
the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed
by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in
patients with active recurrent genital herpes.
This study is not recruiting patients in the United States.